ASX healthcare leader undervalued after share slump
Stocks
ASX healthcare leader undervalued after share slump
The sell-off in this moated healthcare company ignores strong potential for revenue growth and margin improvement.
Expensive ASX star looks vulnerable to slowing sales growth
Stocks
Expensive ASX star looks vulnerable to slowing sales growth
Cochlear’s biggest market segment has matured and it is looking elsewhere for growth.
Overvalued ASX pharma play hits FDA speedbump
Stocks
Overvalued ASX pharma play hits FDA speedbump
We think a delay rather than an outright rejection for this company’s product is the likelier outcome, but the shares still look expensive.
ASX healthcare leader continues to prove the doubters wrong
Stocks
ASX healthcare leader continues to prove the doubters wrong
Niche play with more growth potential than many investors give it credit for.
Undervalued ASX share announces plan to create shareholder value
Stocks
Undervalued ASX share announces plan to create shareholder value
The market cheers update from the company.
Undervalued ASX listed share with strong growth prospects
Stocks
Undervalued ASX listed share with strong growth prospects
The company is poised to take advantage of clear overarching macro revenue drivers.
Ask the analyst: Are IDP Education's woes temporary?
Stocks
Ask the analyst: Are IDP Education's woes temporary?
The global education services provider has gone from stock market darling to one of the ASX's weakest performers. What gives?
Will CEO departure upend ASX healthcare leader?
Stocks
Will CEO departure upend ASX healthcare leader?
Turmoil with the board culuminates in the departure of the CEO.
Should you avoid this highflying ASX share?
Stocks
Should you avoid this highflying ASX share?
A sound business model but the shares are expensive.
Investors overly negative on undervalued ASX share
Stocks
Investors overly negative on undervalued ASX share
Road to profitability is in sight as management continues to take the right steps.
of 5
Viewing 1 to 10 of 44